Medicina,
Год журнала:
2023,
Номер
59(10), С. 1709 - 1709
Опубликована: Сен. 24, 2023
Background:
Since
its
first
report
in
Wuhan,
China,
December
2019,
COVID-19
has
become
a
pandemic,
affecting
millions
of
people
worldwide.
Although
the
virus
primarily
affects
respiratory
tract,
gastrointestinal
symptoms
are
also
common.
The
aim
this
narrative
review
is
to
provide
an
overview
pathophysiology
and
clinical
manifestations
COVID-19.
Methods:
We
conducted
systematic
electronic
search
English
literature
up
January
2023
using
Medline,
Scopus,
Cochrane
Library,
focusing
on
papers
that
analyzed
role
SARS-CoV-2
tract.
Results:
Our
highlights
directly
infects
tract
can
cause
such
as
diarrhea,
nausea/vomiting,
abdominal
pain,
anorexia,
loss
taste,
increased
liver
enzymes.
These
result
from
mucosal
barrier
damage,
inflammation,
changes
microbiota
composition.
exact
mechanism
how
overcomes
acid
gastric
environment
leads
intestinal
damage
still
being
studied.
Conclusions:
vaccination
prevalence
less
severe
symptoms,
long-term
interaction
with
remains
concern.
Understanding
interplay
between
essential
for
future
management
virus.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(16), С. 12962 - 12962
Опубликована: Авг. 19, 2023
We
are
reviewing
the
current
state
of
knowledge
on
virological
and
immunological
correlates
long
COVID,
focusing
recent
evidence
for
possible
association
between
increasing
number
SARS-CoV-2
reinfections
parallel
pandemic
COVID.
The
severity
largely
depends
initial
episode;
in
turn,
this
is
determined
both
by
a
combination
genetic
factors,
particularly
related
to
innate
immune
response,
pathogenicity
specific
variant,
especially
its
ability
infect
induce
syncytia
formation
at
lower
respiratory
tract.
cumulative
risk
COVID
as
well
various
cardiac,
pulmonary,
or
neurological
complications
increases
proportionally
infections,
primarily
elderly.
Therefore,
cases
expected
remain
high
future.
Reinfections
apparently
increase
likelihood
but
less
so
if
they
mild
asymptomatic
children
adolescents.
Strategies
prevent
urgently
needed,
among
older
adults
who
have
higher
burden
comorbidities.
Follow-up
studies
using
an
established
case
definition
precise
diagnostic
criteria
people
with
without
reinfection
may
further
elucidate
contribution
burden.
Although
accumulating
supports
vaccination,
before
after
infection,
preventive
strategy
reduce
more
robust
comparative
observational
studies,
including
randomized
trials,
needed
provide
conclusive
effectiveness
vaccination
preventing
mitigating
all
age
groups.
Thankfully,
answers
not
only
prevention,
also
treatment
options
rates
recovery
from
gradually
starting
emerge.
Antimicrobial Stewardship & Healthcare Epidemiology,
Год журнала:
2023,
Номер
3(1)
Опубликована: Янв. 1, 2023
We
performed
a
systematic
literature
review
and
meta-analysis
on
the
effectiveness
of
coronavirus
disease
2019
(COVID-19)
vaccination
against
post-COVID
conditions
(long
COVID)
among
fully
vaccinated
individuals.Systematic
review/meta-analysis.We
searched
PubMed,
Cumulative
Index
to
Nursing
Allied
Health,
EMBASE,
Cochrane
Central
Register
Controlled
Trials,
Scopus,
Web
Science
from
December
1,
2019,
June
2,
2023,
for
studies
evaluating
COVID-19
vaccine
(VE)
individuals
who
received
two
doses
vaccine.
A
condition
was
defined
as
any
symptom
that
present
four
or
more
weeks
after
infection.
calculated
pooled
diagnostic
odds
ratio
(DOR)
(95%
confidence
interval)
between
unvaccinated
individuals.
Vaccine
estimated
100%
x
(1-DOR).Thirty-two
with
775,931
evaluated
effect
conditions,
which,
twenty-four
were
included
in
meta-analysis.
The
DOR
0.680
CI:
0.523-0.885)
an
VE
32.0%
(11.5%-47.7%).
36.9%
(23.1%-48.2%)
those
before
infection
68.7%
(64.7%-72.2%)
three
stratified
analysis
demonstrated
no
protection
infection.Receiving
complete
prior
contracting
virus
resulted
significant
reduction
throughout
study
period,
including
during
Omicron
era.
increase
when
supplementary
administered.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Фев. 8, 2024
Introduction
Severe
acute
respiratory
syndrome
coronavirus-2
(SARS-CoV-2)
may
trigger
autoimmune
disease
(AD)
through
initial
innate
immune
activation
with
subsequent
aberrations
in
adaptive
cells
leading
to
AD.
While
there
are
multiple
reports
of
incident
AD
diagnosed
after
COVID-19,
the
risk
context
key
circulating
strains
is
unknown.
Methods
TriNetX,
a
global,
federated,
health
research
network
providing
access
electronic
medical
records
across
74
healthcare
organizations,
was
utilized
define
an
adult
cohort
between
January
1,
2020,
and
March
3,
2023.
Exposure
defined
as
COVID-19
diagnosis
(ICD-10
code
or
positive
laboratory
test).
Age-
sex-propensity
score-matched
controls
never
had
diagnosed.
Outcomes
were
assessed
1
month
year
index
date.
Patients
prior
within
date
excluded
from
primary
analysis.
Incidence
ratios
each
assessed.
Results
A
total
3,908,592
patients
included.
Of
24
assessed,
adjusted
for
eight
who
higher
compared
those
no
COVID-19.
Cutaneous
vasculitis
(adjusted
hazard
ratio
(aHR):
1.82;
95%
CI
1.55–2.13),
polyarteritis
nodosa
(aHR:
1.76;
1.15–2.70),
hypersensitivity
angiitis
1.64;
1.12–2.38)
highest
ratios.
Overall,
psoriasis
(0.15%),
rheumatoid
arthritis
(0.14%),
type
diabetes
(0.13%)
incidence
during
study
period,
these,
more
likely
The
any
lower
if
when
Omicron
variants
predominant
strains.
antinuclear
antibody
predictive
Discussion
SARS-CoV-2
be
potential
some
AD,
but
decrease
time
given
apparent
infection
variants.
International Journal of Infectious Diseases,
Год журнала:
2023,
Номер
133, С. 67 - 74
Опубликована: Май 12, 2023
We
aimed
to
identify
trajectories
of
the
evolution
post-COVID-19
condition,
up
2
years
after
symptom
onset.The
ComPaRe
long
COVID
e-cohort
is
a
prospective
cohort
patients
with
symptoms
lasting
at
least
months
SARS-CoV2
infection.
used
trajectory
modeling
different
in
based
on
collected
every
60
days
using
Symptom
Tool.A
total
2197
were
enrolled
between
December
2020
and
July
2022
when
Omicron
variant
was
not
dominant.
Three
condition
identified:
"high
persistent
symptoms"
(4%),
"rapidly
decreasing
(5%),
"slowly
(91%).
Participants
highly
older
more
likely
report
history
systemic
diseases.
They
often
reported
tachycardia,
bradycardia,
palpitations,
arrhythmia.
rapidly
younger
confirmed
diarrhea
back
pain.
slowly
have
functional
diseases.Most
improve
over
time,
while
5%
rapid
improvement
onset
4%
condition.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Июль 20, 2023
Background
The
role
of
adaptive
immune
responses
in
long
COVID
remains
poorly
understood,
with
contrasting
hypotheses
suggesting
either
an
insufficient
antiviral
response
or
excessive
associated
inflammatory
damage.
To
address
this
issue,
we
set
to
characterize
humoral
and
CD4+
T
cell
patients
prior
SARS-CoV-2
vaccination.
Methods
Long
who
were
seropositive
(LC+,
n=28)
seronegative
(LC-,
n=23)
by
spike
ELISA
assay
recruited
based
on
(i)
initial
infection
documented
PCR
the
conjunction
three
major
signs
COVID-19
(ii)
persistence
resurgence
at
least
3
symptoms
for
over
months.
They
compared
resolved
(RE,
n=29)
uninfected
control
individuals
(HD,
n=29).
Results
spectrum
persistent
proved
similar
both
groups,
a
trend
higher
number
group
(median=6
vs
4.5;
P=0.01).
use
highly
sensitive
S-flow
enabled
detection
low
levels
spike-specific
IgG
22.7%
ELISA-seronegative
(LC-)
patients.
In
contrast,
uniformly
high
LC+
RE
groups.
Multiplexed
antibody
analyses
30
different
viral
antigens
showed
that
LC-
had
defective
all
proteins
tested
but
most
cases
preserved
other
viruses.
A
primary
line
revealed
detectable
SARS-CoV-2-specific
CD4
39.1%
patients,
while
frequencies
Correlation
overall
strong
associations
between
cellular
responses,
exceptions
group.
Conclusions
These
findings
provide
evidence
two
types
COVID.
Seropositive
coordinated
as
those
recovered
specific
cells
and/or
antibodies
close
half
(52.2%).
divergent
sharing
comparable
raise
possibility
multiple
etiologies
iScience,
Год журнала:
2024,
Номер
27(4), С. 109536 - 109536
Опубликована: Март 19, 2024
This
prospective
study
aimed
to
determine
the
prevalence
of
long
COVID
in
patients
hospitalized
for
SARS-CoV-2
infection
from
March
2020
July
2022
and
assess
impact
different
viral
lineages.
A
total
2,524
were
followed
up
12
months,
with
persistent
symptoms
reported
35.2%
at
one
month,
decreasing
thereafter.
Omicron
variant
initially
showed
higher
symptom
intensity,
but
this
trend
diminished
over
time.
Certain
lineages,
notably
Delta
lineages
AY.126
AY.43,
sublineages
BA.1.17,
BA.2.56,
BA.5.1,
consistently
correlated
more
severe
symptoms.
Overall,
severity
similar
across
variants.
Specific
may
influence
post-COVID
sequelae
persistence
severity.
